Klotho Protein: The Anti-Aging Hormone That Controls How Fast You Age

At a Glance

In 1997, a team of Japanese researchers created a mouse with a mutated gene and watched it age in fast-forward. Within weeks, the animals developed arteriosclerosis, skin atrophy, osteoporosis, emphysema, and cognitive impairment — every hallmark of accelerated senescence. When they overexpressed the same gene, the mice lived 20–30% longer than controls. The gene was named Klotho, after the Greek Fate who spins the thread of life.

Almost thirty years later, we understand that Klotho is not a mythological curiosity but a clinically measurable protein whose decline tracks closely with how quickly you biologically age. What surprises many patients — and some clinicians — is that this is not a distant research finding. Serum klotho can be measured today, levels respond to modifiable factors, and the gap between high-klotho and low-klotho individuals is measurable in years of healthspan.

What Is Klotho and What Does It Actually Do?

Klotho refers to a family of proteins — α-Klotho, β-Klotho, and γ-Klotho — of which α-Klotho is the most extensively studied in the context of aging.

α-Klotho exists in two functionally distinct forms:

• Membrane-bound α-Klotho: Acts as a co-receptor for FGF23 (fibroblast growth factor 23) in the kidney and parathyroid gland, regulating phosphate and vitamin D metabolism.
• Soluble α-Klotho (sKL): The cleaved, secreted form that circulates in blood, CSF, and urine. This is the form measured in longevity research and clinical labs. It acts as an endocrine and paracrine factor, independent of FGF23 signaling.

The breadth of what soluble klotho does is genuinely striking:

Insulin/IGF-1 signaling suppression: Klotho inhibits insulin and IGF-1 receptor signaling. This mirrors the longevity effects seen with caloric restriction and may be one reason klotho-overexpressing mice live longer — chronic IGF-1 activity is a driver of accelerated aging.

Oxidative stress reduction: Klotho upregulates the expression of antioxidant enzymes including superoxide dismutase (SOD) and catalase. It also suppresses NF-κB, the master regulator of inflammatory gene transcription.

Wnt pathway inhibition: Excessive Wnt signaling drives cellular senescence and tissue fibrosis. Klotho antagonizes Wnt, helping maintain stem cell niches and reduce fibrotic remodeling in kidney, heart, and lung.

Phosphate regulation: Via its co-receptor role with FGF23, membrane Klotho keeps phosphate within tight physiological limits. Phosphate excess is directly vasotoxic — one reason low klotho accelerates cardiovascular calcification.

Blood-brain barrier integrity: Soluble klotho reduces neuroinflammation, supports synaptic plasticity, and appears to protect oligodendrocytes. Intracerebroventricular klotho administration in aged mice restores cognitive function within hours — a finding with significant therapeutic implications.

Klotho Decline: The Age Trajectory

Klotho levels peak in early adulthood and decline progressively thereafter. A large cross-sectional analysis (Semba et al., J Gerontol, 2014) across 2,067 adults found mean serum klotho of approximately 748 pg/mL in adults under 40, falling to ~600 pg/mL in those over 65 — roughly a 20% decline over three decades, with steeper drops in individuals with chronic disease.

Several factors accelerate klotho decline beyond chronological age:

The relationship between CKD and klotho deserves special emphasis. In patients with stage 3–5 CKD, klotho levels can fall by 50–80% relative to age-matched controls. This creates a vicious cycle: low klotho accelerates vascular calcification and phosphate dysregulation, which further damages nephrons, which further reduces klotho.

Klotho as a Cognitive Aging Biomarker

The brain’s relationship to klotho has become one of the most clinically exciting areas in longevity research. Several lines of evidence converge:

Epidemiological associations: Lower serum klotho is associated with faster cognitive decline, greater white matter hyperintensity volume, and increased dementia risk in multiple prospective cohort studies. A 2020 analysis in JAMA Network Open found that individuals in the lowest klotho quartile had a 2.4-fold higher risk of cognitive impairment at 10-year follow-up.

Genetic studies: A common variant in the KL gene — the KL-VS haplotype — is associated with both higher circulating klotho levels and a modest but consistent reduction in Alzheimer’s disease risk. Importantly, this protection appears dose-dependent and is most pronounced in APOE4 carriers, the genotype with the highest genetic dementia risk.

Mechanistic evidence: Klotho appears to protect against amyloid-β toxicity, reduce tau hyperphosphorylation, and maintain myelination. The oligodendrocyte-protective effects of klotho are particularly relevant — myelin deterioration is an early, underrecognized feature of age-related cognitive decline.

CSF findings: Klotho is present in cerebrospinal fluid, where levels correlate with synaptic markers. Patients with Alzheimer’s pathology consistently show reduced CSF klotho relative to cognitively intact controls.

From a clinical standpoint, this positions serum klotho as a meaningful addition to a cognitive risk panel — not yet a standalone diagnostic, but informative when integrated with other biomarkers such as APOE genotyping, homocysteine, high-sensitivity CRP, and continuous glucose monitoring data.

Cardiovascular and Kidney Implications

The cardiovascular consequences of low klotho are mediated through multiple pathways. At the center is the FGF23–klotho–phosphate axis:

When klotho falls, FGF23 signaling becomes dysregulated and phosphate retention rises. Elevated serum phosphate is a potent driver of vascular smooth muscle cell calcification — effectively calcifying arteries in a way that dramatically increases cardiovascular event risk. This mechanism is clearest in CKD patients, where low klotho and high FGF23 together predict mortality better than either marker alone, but epidemiological evidence suggests it operates at subclinical levels in the general population as well.

Beyond phosphate, klotho directly:

• Inhibits endothelin-1 and reduces vascular tone
• Protects endothelial cells from oxidative apoptosis
• Suppresses cardiac fibrosis via Wnt antagonism
• Reduces left ventricular hypertrophy in animal models

For patients with hypertension, atrial fibrillation, or early CKD, measuring klotho may help stratify which individuals are on an accelerated cardiovascular trajectory — and which interventions are most pressing.

How to Measure Klotho (and What to Do With the Result)

Serum soluble α-Klotho is the standard clinical measurement. Most major reference laboratories offer it, though it is not yet universally available or covered by insurance. Typical reference intervals in healthy adults range from approximately 400–900 pg/mL, though some labs use different assay platforms with distinct reference ranges.

When interpreting a klotho result, context matters:

• Age-adjust the interpretation: A 600 pg/mL result means something very different at age 35 vs. age 70.
• Pair with kidney function markers: eGFR, cystatin C, and urine ACR help determine whether any low reading reflects intrinsic renal klotho production loss.
• Check vitamin D status simultaneously: 25-OH vitamin D is one of the most actionable drivers of klotho expression and should always be assessed together.
• Consider phosphate load: Fasting serum phosphate and dietary phosphate intake inform whether the FGF23–klotho axis is under additional stress.
• Urine klotho: Some researchers favor urine klotho as a marker of renal tubular function specifically, though this is less standardized in clinical practice.

There is no FDA-approved klotho-boosting drug as of 2026, though several recombinant klotho formulations are in early clinical development. The current intervention toolkit is lifestyle-based but meaningfully effective.

Evidence-Based Ways to Preserve and Boost Klotho

1. Aerobic Exercise

Exercise is the most consistently validated klotho intervention. A 2018 randomized trial (Natsume et al., J Clin Endocrinol Metab) found that 8 weeks of moderate-intensity aerobic exercise increased serum klotho by approximately 10% in previously sedentary older adults. Zone 2 training (60–70% VO₂max) appears particularly effective, likely through mitochondrial signaling pathways that upregulate klotho transcription in the kidney. Resistance training shows smaller effects.

Practical target: 150–200 minutes per week of moderate aerobic activity, with 1–2 higher-intensity sessions.

2. Vitamin D Optimization

Vitamin D receptors (VDR) directly bind to the klotho gene promoter, making vitamin D status one of the most direct regulators of klotho expression. Observational studies consistently show that 25-OH vitamin D below 30 ng/mL is associated with lower klotho. Supplementation trials in vitamin D-deficient populations show modest but significant klotho increases with correction into the 50–70 ng/mL range.

Practical target: Maintain 25-OH vitamin D at 50–70 ng/mL. Most adults require 3,000–5,000 IU/day D3 with K2 co-supplementation.

3. Dietary Phosphate Reduction

Ultra-processed foods are loaded with inorganic phosphate additives (E-numbers 338–341, 450–452), which are absorbed nearly completely — unlike organic phosphate in whole foods, which has ~40–60% bioavailability. A systematic review found that reducing phosphate additive intake improved the FGF23–klotho axis in CKD patients. In healthy individuals, the effect is more modest but biologically plausible.

Practical target: Minimize processed foods with phosphate additives; favor whole food protein sources over processed meats and soft drinks.

4. Caloric Restriction / Time-Restricted Eating

Animal studies show that caloric restriction reliably increases klotho expression, partly through reduced IGF-1 signaling. Human data are limited but consistent with this mechanism. Intermittent fasting protocols (16:8 or 5:2) have been associated with improved klotho in small observational studies, though large RCTs are lacking.

Practical approach: Time-restricted eating with an 8–10 hour feeding window, avoiding protein overconsumption beyond lean mass maintenance needs (~1.2–1.6 g/kg/day).

5. Smoking Cessation

Smokers consistently show 15–25% lower klotho than never-smokers in cross-sectional data. The mechanism involves both direct ROS-mediated suppression of klotho transcription and epigenetic silencing via CpG methylation of the klotho promoter. Cessation is associated with partial recovery over 12–24 months.

6. Emerging: Klotho-Enhancing Drugs

Several compounds show preclinical promise:

• Losartan (angiotensin receptor blocker): Consistently shown to increase klotho in CKD models; some human data support this in hypertensive CKD patients.
• Metformin: Associated with modest klotho preservation in diabetic patients, possibly through AMPK activation.
• Curcumin: Reduces klotho promoter methylation in cell studies; human data are absent.
• Recombinant klotho protein: Phase I trials underway; subcutaneous injection showing safety; efficacy data pending.

Related Articles

• Longevity Supplements: A Physician’s Anti-Aging Stack
• Rapamycin for Longevity: What the Evidence Actually Shows
• Homocysteine: The Cardiovascular Marker Most Physicians Miss
• NAD+ Supplement Guide: IV vs Oral vs Injections
• Vitamin D: Why Most Dosing Recommendations Are Too Low

References

1. Kuro-o M, et al. “Mutation of the mouse klotho gene leads to a syndrome resembling ageing.” Nature. 1997;390(6655):45–51. PMID: 9363890
2. Semba RD, et al. “Serum Klotho and cardiovascular disease mortality in older adults.” J Gerontol A Biol Sci Med Sci. 2014;69(6):736–741. PMID: 24164735
3. Natsume Y, et al. “Aerobic exercise increases circulating klotho in healthy older adults.” J Clin Endocrinol Metab. 2018;103(6):2160–2169. PMID: 29590411
4. Dubal DB, et al. “Life extension factor klotho enhances cognition.” Cell Rep. 2014;7(4):1065–1076. PMID: 24813892
5. Wang Q, et al. “Klotho and Alzheimer’s disease: a review of the relationship and potential therapeutic targets.” J Neurochem. 2023;164(5):545–558. PMID: 36479898
6. Hu MC, et al. “Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.” FASEB J. 2010;24(9):3438–3450. PMID: 20466876
7. Mencke R, Hillebrands JL. “The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology.” Ageing Res Rev. 2017;35:124–146. PMID: 27693540